Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Sci. Signal., 21 July 2009
Vol. 2, Issue 80, p. ra36
[DOI: 10.1126/scisignal.2000308]
RESEARCH ARTICLES
Editor's Summary
Dyskinesia Relief
In its role as a regulator of cell growth, the mammalian complex of rapamycin (mTOR) phosphorylates several proteins involved in protein synthesis, such as 4E-BP (eukaryotic initiation factor 4E binding protein) and S6K (p70 S6 kinase), in response to growth factors and nutrient availability. Santini et al. show that L-DOPA, the most commonly used medication to alleviate the immobility and rigidity (akinesia) characteristic of Parkinson’s disease (PD), also stimulates the rapamycin-sensitive mTOR complex 1 (mTORC1). In a mouse model of PD, L-DOPA treatment increased phosphorylation of several direct and indirect mTOR targets, including S6K, its substrate ribosomal protein S6 (S6), 4E-BP, and eukaryotic initiation factor 4E (eIF4E). These phosphorylation increases required the activity of dopamine D1 receptors and extracellular signal–regulated kinase (ERK). Furthermore, increased phosphorylation of S6K, S6, 4E-BP, and eIF4E correlated with stronger abnormal involuntary movements (AIMs), a measure of dyskinesia (a side effect of L-DOPA that limits its clinical use). Administration of rapamycin, which predominantly inhibits mTORC1, decreased the severity of AIMs without affecting the ability of L-DOPA to reduce akinesia. Thus, the mTORC1 signaling pathway could be targeted in PD patients suffering from the dyskinesia associated with L-DOPA treatment.
Citation: E. Santini, M. Heiman, P. Greengard, E. Valjent, G. Fisone, Inhibition of mTOR Signaling in Parkinson’s Disease Prevents L-DOPA–Induced Dyskinesia. Sci. Signal.2, ra36 (2009).
The editors suggest the following Related Resources on Science sites:
In Science Signaling
EDITORIAL GUIDES
Nancy R. Gough (27 March 2012) Sci. Signal.5 (217), eg4.
[DOI: 10.1126/scisignal.2003044] |Abstract »|Full Text »|PDF »
EDITORS' CHOICE
Nancy R. Gough (2 August 2011) Sci. Signal.4 (184), ec214.
[DOI: 10.1126/scisignal.4184ec214] |Abstract »
PODCASTS
Wei Wong and Annalisa M. VanHook (21 July 2009) Sci. Signal.2 (80), pc13.
[DOI: 10.1126/scisignal.280pc13] |Abstract »|Full Text »|Podcast »
PERSPECTIVES
Eric Klann (21 July 2009) Sci. Signal.2 (80), pe42.
[DOI: 10.1126/scisignal.280pe42] |Abstract »|Full Text »|PDF »
EDITORIAL GUIDES
Wei Wong (21 July 2009) Sci. Signal.2 (80), eg9.
[DOI: 10.1126/scisignal.280eg9] |Abstract »|Full Text »|PDF »
EDITORIAL GUIDES
Nancy R. Gough (21 April 2009) Sci. Signal.2 (67), eg5.
[DOI: 10.1126/scisignal.267eg5] |Abstract »|Full Text »|PDF »
PERSPECTIVES
David A. Guertin and David M. Sabatini (21 April 2009) Sci. Signal.2 (67), pe24.
[DOI: 10.1126/scisignal.267pe24] |Abstract »|Full Text »|PDF »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The Pharmacology of L-DOPA-Induced Dyskinesia in Parkinson's Disease.
P. Huot, T. H. Johnston, J. B. Koprich, S. H. Fox, and J. M. Brotchie (2013)
Pharmacol. Rev.
65, 171-222
|Abstract »|Full Text »|PDF »
Consolidation and translation regulation.
S. Gal-Ben-Ari, J. W. Kenney, H. Ounalla-Saad, E. Taha, O. David, D. Levitan, I. Gildish, D. Panja, B. Pai, K. Wibrand, et al. (2012)
Learn. Mem.
19, 410-422
|Abstract »|Full Text »|PDF »
Dopamine- and cAMP-regulated Phosphoprotein of 32-kDa (DARPP-32)-dependent Activation of Extracellular Signal-regulated Kinase (ERK) and Mammalian Target of Rapamycin Complex 1 (mTORC1) Signaling in Experimental Parkinsonism.
E. Santini, M. Feyder, G. Gangarossa, H. S. Bateup, P. Greengard, and G. Fisone (2012)
J. Biol. Chem.
287, 27806-27812
|Abstract »|Full Text »|PDF »
G{alpha}olf Mutation Allows Parsing the Role of cAMP-Dependent and Extracellular Signal-Regulated Kinase-Dependent Signaling in L-3,4-Dihydroxyphenylalanine-Induced Dyskinesia.
C. Alcacer, E. Santini, E. Valjent, F. Gaven, J.-A. Girault, and D. Herve (2012)
J. Neurosci.
32, 5900-5910
|Abstract »|Full Text »|PDF »
Tonic Dopamine Induces Persistent Changes in the Transient Potassium Current through Translational Regulation.
E. W. Rodgers, W.-D. C. Krenz, and D. J. Baro (2011)
J. Neurosci.
31, 13046-13056
|Abstract »|Full Text »|PDF »
The Physiology, Signaling, and Pharmacology of Dopamine Receptors.
Role of Aberrant Striatal Dopamine D1 Receptor/cAMP/Protein Kinase A/DARPP32 Signaling in the Paradoxical Calming Effect of Amphetamine.
F. Napolitano, A. Bonito-Oliva, M. Federici, M. Carta, F. Errico, S. Magara, G. Martella, R. Nistico, D. Centonze, A. Pisani, et al. (2010)
J. Neurosci.
30, 11043-11056
|Abstract »|Full Text »|PDF »
Roles of Fragile X Mental Retardation Protein in Dopaminergic Stimulation-induced Synapse-associated Protein Synthesis and Subsequent {alpha}-Amino-3-hydroxyl-5-methyl-4-isoxazole-4-propionate (AMPA) Receptor Internalization.
